AFRICA: Atorvastatin Plus Fenofibric Acid (TriLipix) in the Reduction of Intermediate Coronary Atherosclerosis

Inclusion Criteria:

1. Age 18-85

2. CAC 30-400, within 12 months of screening visit, OR intermediate stenosis oncoronary artery CTA or invasive angiography (40-69% visual estimation) without thepresence of obstructive (≥70% visual estimation) Stenosis within 3 months ofscreening visit

3. LDL-C ≥ 100 mg/dL and LDL-C ≤190 mg/dL at screening or baseline visit

4. TG>150 mg/dL and TG/HDL>3.5 at screening or baseline visit

5. 10 Year Framingham risk score of ≤ 10%

6. Ability and willingness to provide consent and Authorization for use of PHI

Exclusion Criteria:

1. Previous coronary revascularization (PCI, CABG)

2. Current lipid lowering therapy (includes statins, fibrates, niacin, omega 3 agents,intestinal cholesterol absorption inhibitors, cholestatic cholesterol absorptionagents and other anti-lipemic agents.)

3. Known genetic form of hypercholesterolemia (e.g. familial hypercholesterolemia,etc.)

4. Creatinine 1.5 mg/dL or greater at baseline visit

5. Fasting serum triglycerides 500 mg/dL or greater at screening or baseline visit

6. Inability to perform CTA:

7. Arrhythmia precluding diagnostic CT examination

8. Known moderate or severe allergy to iodine-based contrast agents (mild priorreactions that could be treated as an outpatient or that could be prevented bypre-medication in the past do not constitute exclusion)

9. Uncontrolled hypertension (SBP>180 mmHg or DBP>130 mmHg on stable treatment)

10. Decompensated heart failure (NYHA class IV) at the time of enrollment

11. Known Pregnancy

12. Inability or unwillingness to consent and Authorization for use of PHI

13. Presence of any co-morbidity that makes life expectancy less than 24 months

14. Inability or unwillingness to comply with follow up procedures